MARKET

CORV

CORV

Correvio Pharma Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3582
-0.0126
-3.40%
After Hours: 0.3630 +0.0048 +1.34% 19:53 01/24 EST
OPEN
0.3710
PREV CLOSE
0.3708
HIGH
0.3750
LOW
0.3580
VOLUME
2.59M
TURNOVER
--
52 WEEK HIGH
4.440
52 WEEK LOW
0.3490
MARKET CAP
18.10M
P/E (TTM)
-0.3979
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CORV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CORV News

  • CORV DEADLINE ALERT: ROSEN, INVESTOR COUNSEL, Reminds Correvio Pharma Corp. Investors of Important February 10th Deadline in Securities Class Action - CORV
  • ACCESSWIRE.2d ago
  • Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Correvio Pharma Corporation
  • GlobeNewswire.2d ago
  • SHAREHOLDER ALERT: CTAS and CORV: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With Losses Exceeding $100K of Class Action Deadlines
  • ACCESSWIRE.2d ago
  • SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Correvio Pharma Corporation of Class Action Lawsuit and Upcoming Deadline - CORV
  • ACCESSWIRE.3d ago

More

Industry

Pharmaceuticals
-1.84%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About CORV

Correvio Pharma Corp is a Canada-based specialty pharmaceutical company. It provides brands that meet the needs of acute care physicians and patients. It develops, acquires and commercializes brands for the in-hospital, acute care market segment. The following is its portfolio of approved and marketed brands: Xydalba, for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP); Brinavess for the conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome, as well as Esmocard and Esmocard Lyo, a short-acting betablocker used to control rapid heart rate in a number of cardiovascular indications. Its pipeline of product candidates includes Trevyent, a drug device combination that is designed to deliver treprostinil.
More

Webull offers Correvio Pharma Corp (CORV) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.